Plant and bacterial extracts exhibiting retinol-like activity

Botanical and bacterial extracts are used topically to mimic retinol's effects on skin, addressing aging and acne while enhancing skin health and barrier function without irritation.

JP7591695B2Active Publication Date: 2024-11-29JOHNSON & JOHNSON CONSUMER INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021504340
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-23
Filing Date
2019-07-24
Publication Date
2024-11-29
Estimated Expiration
2039-07-24

AI Technical Summary

Technical Problem

Existing skin treatments for aging and acne using synthetic retinoids are limited by skin irritation, and there is a need for natural compounds with retinol-like activity to address signs of aging and improve skin barrier function.

Method used

Topical application of botanical extracts from Acronychia, Lycaria, Calendula, and bacterial extracts from Actinomyces species, such as Acronythia acidula, Lycaria vernicosa, Calendula officinalis, and Actinomyces, to upregulate retinol-responsive genes and improve skin health.

Benefits of technology

The extracts demonstrate retinol-like activity by upregulating genes associated with skin health, reducing signs of aging, improving skin barrier function, and treating acne without the irritation of synthetic retinoids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591695000010
    Figure 0007591695000010
  • Figure 0007591695000011
    Figure 0007591695000011
  • Figure 0007591695000001
    Figure 0007591695000001
Patent Text Reader

Abstract

Methods of treating skin and other tissues by applying plant or bacterial extracts and extracts of specific plants or bacteria, such as Acronitzia acidula, Licoricea vernicosa, Calendula officinalis, Fenugreek, or Actinomyces bacteria, to the skin or other tissues are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions having retinol-like activity and methods of using the compositions to treat human tissues, including skin, hair, nails, oral mucosa, nasal mucosa, vaginal mucosa, and the like. [Background technology]

[0002] Human skin undergoes certain aging processes, some of which are due to intrinsic processes (e.g. chronoaging) and some due to extrinsic factors (e.g. photoaging). In addition, temporary or even permanent changes to the skin may occur, such as acne, oily or dry skin, keratosis, rosacea, photosensitivity, inflammatory, erythematous, and allergic or autoimmune reactions, such as dermatitis and photodermatoses.

[0003] Consequences of the aging process described above include thinning of the skin, weakening of the epidermis and dermis interdigitation, and a decrease in the number of cells and blood vessel supply, which often leads to the formation of fine lines and wrinkles and may result in pigmentation defects.

[0004] Retinoids have been used to treat skin conditions caused by intrinsic aging, extrinsic factors, or skin diseases.However, despite the beneficial effects of retinoid treatment, its benefits are limited due to the skin irritation of retinoids.These side effects can limit the use of retinoids.All retinoids used in cosmetic products are of synthetic origin, and there is a great acceptance from cosmetic users for natural compounds with retinol-like activity and skin treatment effects.

[0005] To date, the search for alternative or natural compounds to replace retinoids has met with some success in treating age-related skin conditions such as skin atrophy, photoaging, and in reducing the appearance of wrinkles, fine lines, stretch marks, or cellulite.

[0006] U.S. Patent Application No. 9,220,928, assigned to Ecobiotics LTD, discloses compounds derived from plants of the genus Acronitia, including 3-(4-farnesyloxyphenyl)-propionic acid, for use as antioxidants, antibacterial agents, antiparasitic agents, anti-inflammatory agents, cancer chemopreventive agents, food additives and / or fragrance ingredients. However, the patent does not identify any anti-aging properties associated with the compositions therein.

[0007] U.S. Patent Application Publication No. 2013 / 0259815, assigned to Johnson & Johnson Consumer Companies, Inc., discloses a method for lightening the skin by applying to the skin certain aromatic compounds or plant extracts, including plants of the genus Acronitia, that contain such compounds.

[0008] Applicants have unexpectedly discovered that certain extracts, including plant extracts from plants of the genera Acronitia, Licaria, Calendula and Leucanthemum, and bacterial extracts of the genus Actinomyces, exhibit retinol-like bioactivity and / or other consumer-desirable properties for use on skin and other human tissues.Such extracts can be used on the skin to provide significant anti-aging, skin barrier improvement and moisturization, anti-acne, and other benefits normally associated with retinol.Such extracts may be used, for example, on oral, nasal, and vaginal mucosa. Summary of the Invention [Problem to be solved by the invention]

[0009] The present invention relates to extracts that exhibit, for example, retinol-like biological activity in skin, including upregulation of retinol-responsive genes such as RARg, CRABP2, HbEGF, HAS3, and UGCG in human skin explant cultures. Additionally, the present invention relates to methods of using such plant or bacterial extracts to treat signs of aging, improve skin barrier function, and provide anti-acne benefits. [Means for solving the problem]

[0010] The present invention relates to a method for treating the signs of skin aging, comprising topically applying to skin in need of treatment for the signs of skin aging a composition comprising an extract selected from the group consisting of an extract of Acronychia acidula, an extract of Licaria vernicosa, an extract of Calendula officinalis, an extract of Trigonella foenum-graecum, an extract of Actinomyces bacteria, and combinations thereof.

[0011] The present invention also relates to a method for improving skin barrier properties, comprising topically applying to skin in need of improved skin barrier function and moisturization a composition comprising an extract selected from the group consisting of an extract of Acronitia acidula, an extract of Licaria vernicosa, an extract of Calendula officinalis, an extract of Fenugreek, an extract of Actinomyces, and combinations thereof.

[0012] The present invention further relates to a method of treating acne comprising topically applying to skin in need of acne treatment a composition comprising an extract selected from the group consisting of an extract of Acronitzia acidula, an extract of Licaria vernicosa, an extract of Calendula officinalis, an extract of Fenugreek, an extract of Actinomyces, and combinations thereof.

[0013] The present invention relates to a method for treating the signs of skin aging, comprising topically applying to skin in need of treatment for the signs of skin aging a composition comprising an extract of Acronitzia acidula.

[0014] The present invention also relates to a method for improving skin barrier properties, comprising topically applying a composition comprising an extract of Acronitzia acidula to skin in need of improved skin barrier function and moisturization.

[0015] The present invention further relates to a method of treating acne comprising topically applying to skin in need of acne treatment a composition comprising an extract of Acronitzia acidula.

[0016] The present invention also relates to a method of treating the signs of skin aging, comprising topically applying to skin in need of treatment for the signs of skin aging a composition comprising an extract of Licaria vernicosa.

[0017] The present invention also relates to a method for improving skin barrier properties, comprising topically applying a composition comprising an extract of Licaria vernicosa to skin in need of improved skin barrier function and moisturization.

[0018] The present invention further relates to a method of treating acne comprising topically applying to skin in need of acne treatment a composition comprising an extract of Licaria vernicosa.

[0019] The present invention also relates to a method of treating the signs of skin aging, comprising topically applying to skin in need of treatment for the signs of skin aging a composition comprising an extract of Calendula officinalis.

[0020] The present invention also relates to a method for improving skin barrier properties, comprising topically applying a composition comprising an extract of Calendula officinalis to skin in need of improved skin barrier function and moisturization.

[0021] The present invention further relates to a method of treating acne comprising topically applying to skin in need of acne treatment a composition comprising an extract of Calendula officinalis.

[0022] The present invention also relates to a method of treating the signs of skin aging comprising topically applying to skin in need of treatment for the signs of skin aging a composition comprising an extract of fenugreek.

[0023] The present invention also relates to a method for improving skin barrier properties, comprising topically applying a composition comprising an extract of fenugreek to skin in need of improved skin barrier function and moisturization.

[0024] The present invention further relates to a method of treating acne comprising topically applying to skin in need of acne treatment a composition comprising an extract of fenugreek.

[0025] The present invention also relates to a method of treating the signs of skin aging, comprising topically applying to skin in need of treatment for the signs of skin aging a composition comprising an extract of Actinomyces bacteria.

[0026] The present invention also relates to a method for improving skin barrier properties, comprising topically applying a composition comprising an extract of Actinomyces bacteria to skin in need of improved skin barrier function and moisturization.

[0027] The present invention further relates to a method of treating acne comprising topically applying to skin in need of acne treatment a composition comprising an extract of Actinomyces bacteria. [Brief description of the drawings]

[0028] [Figure 1] Photographs of skin explants including untreated, vehicle treated, treated with 1% Acronitzia acidula extract (E1) and treated with 0.1% retinol as described in Example 4. [Diagram 2] Photographs of skin explants shown in Example 5, including untreated, vehicle treated, treated with 1% Acronitzia acidula extract (E1), and treated with 0.1% retinol. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] It is believed that one skilled in the art can utilize the present invention to its fullest extent based on the description herein. The following specific embodiments are to be construed as merely illustrative, and are not to be construed as limiting the following disclosure in any way.

[0030] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.In addition, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference.As used herein, all percentages are by weight / volume of the total composition unless otherwise specified.

[0031] term As used herein, a composition that is "essentially free" of a component means that the composition contains about 2% by weight or less of the component based on the total weight of the composition. In one embodiment, a composition that is essentially free of a component contains about 1% by weight or less of the component based on the total weight of the composition, more preferably about 0.5% by weight or less, more preferably about 0.1% by weight or less, more preferably about 0.05% by weight or less, more preferably about 0.01% by weight or less of the component. In certain embodiments, a composition that is essentially free of a component does not contain the component, i.e., the component is not present in the composition.

[0032] As used herein, "cosmetically acceptable" means that the ingredient described by this term is suitable for use in contact with tissue (e.g., skin or hair) without undue toxicity, incompatibility, instability, irritation, allergic reaction, etc. As recognized by those skilled in the art, cosmetically acceptable salts are acidic / anionic or basic / cationic salts. Cosmetically acceptable salts derived from inorganic bases include, for example, sodium or potassium salts. Cosmetically acceptable salts derived from organic bases include, for example, salts formed with primary, secondary, or tertiary amines, etc.

[0033] As used herein, "cosmetic," particularly as it pertains to the appearance of tissue or skin, refers to cosmetic substances or preparations that maintain, restore, impart, embellish or enhance a physically pleasing appearance or that appear to enhance beauty or youthfulness.

[0034] As used herein, the term "safe and effective amount" means an amount sufficient to induce the desired effect, but small enough to avoid serious side effects. A safe and effective amount of a compound, extract, or composition will vary depending, for example, on the age, health condition, and environmental exposure of the end user, the duration and nature of the treatment, the specific compound, extract, ingredient, or composition used, the specific cosmetically acceptable carrier used, and similar factors.

[0035] As used herein, "treatment" or "treating" refers to the improvement, prevention, or amelioration of a condition, disease, or disorder, or at least one discernible symptom thereof. In one embodiment, "treatment" or "treating" refers to the improvement, prevention, or amelioration of at least one measurable physical parameter associated with the condition, disease, or disorder being treated, which is not necessarily discernible in or by the subject being treated. In another embodiment, "treatment" or "treating" refers to inhibiting or slowing the progression of the condition, disease, or disorder, either physically (e.g., stabilization of a discernible symptom), physiologically (e.g., stabilization of a physical parameter), or both. In another embodiment, "treatment" or "treating" refers to delaying the onset of the condition, disease, or disorder.

[0036] In certain embodiments, the compositions of the invention are administered as a prophylactic measure. As used herein, "prevention" or "preventing" refers to reducing the risk of acquiring a given condition, disease, or disorder.

[0037] The composition of the present invention is suitable for treating or preventing signs of skin aging.As used herein, "skin aging signs" include the presence of fine lines and wrinkles, loss of elasticity, uneven skin, and age spots.In a particularly preferred embodiment, the signs of aging are the presence of fine lines and wrinkles and / or loss of elasticity.

[0038] As used herein, "wrinkles" includes fine lines, fine wrinkles, or coarse wrinkles. Examples of wrinkles include, but are not limited to, fine lines around the eyes (e.g., "crow's feet"), wrinkles on the forehead and cheeks, lines between the eyebrows, and laugh lines around the mouth.

[0039] The compositions of the invention are suitable for improving the texture of the skin or for improving the firmness of the skin.

[0040] As used herein, "improving skin texture" means smoothing the surface of the skin to remove either bumps or crevices in the skin surface.

[0041] As used herein, "improving skin firmness" means enhancing skin firmness or elasticity, preventing loss of skin firmness or elasticity, or preventing or treating sagging, loose and lax skin.

[0042] As used herein, "loss of elasticity" includes loss of elasticity or structural integrity of skin or tissue, including, but not limited to, sagging, loose and flaccid tissue. Loss of elasticity or structural integrity of tissue can be the result of a number of factors, including, but not limited to, disease, aging, hormonal changes, mechanical trauma, environmental damage, or the application of products, such as cosmetic or pharmaceutical products, to the tissue.

[0043] As used herein, "uneven skin" means a skin condition associated with diffuse or patchy pigmentation that can be classified as hyperpigmentation, such as post-inflammatory hyperpigmentation.

[0044] As used herein, "age spots" refers to a skin condition associated with redness or erythema.

[0045] As used herein, "age spots" refers to a skin condition associated with discrete pigmentation, such as small areas of darker pigmentation that can occur on the face and hands.

[0046] Signs of skin aging also include the presence of a decrease in skin thickness, as well as abnormal or decreased synthesis of glycoproteins, including collagen, glycosaminoglycans, proteoglycans, elastin, or fibronectin. In one embodiment, the sign of aging is selected from abnormal or decreased synthesis of glycoproteins, including collagen, glycosaminoglycans, proteoglycans, elastin, or fibronectin. In another embodiment, the sign of skin aging is decreased synthesis of collagen or elastin.

[0047] The composition is also suitable for treating or preventing acne.As used herein, "acne" refers to a disorder resulting from the action of hormones and other substances on sebaceous glands and hair follicles, typically resulting in the formation of clogged pores and inflammatory or non-inflammatory lesions on the skin.In particular, it relates to age spots, lesions, or pimples, pre-emergent pimples, blackheads, and / or whiteheads.As used herein, "pre-emergent pimples" are inflammatory vesicles that are not visually evident to the naked eye (e.g., as lesions) on the surface of the skin.

[0048] The compositions of the present invention are also suitable for the treatment or prevention of rosacea. As used herein, "rosacea" refers to skin having persistent erythema with or without papules, pustules, or nodules.

[0049] The composition of the present invention is also suitable for treating skin that requires improvement of skin barrier function and moisturization.As used in the present invention, "skin that requires improvement of skin barrier function and moisturization" refers to skin that is lacking in moisture, lacking in sebum, cracked, dry, itchy, scaly, xerosis, dehydrated, lacking in suppleness, lacking in radiance, dull, or lacking in lipids, but is not limited thereto.

[0050] The compositions of the present invention are also suitable for enhancing endogenous hyaluronic acid ("HA") levels in the skin, providing improved hydration and ameliorating the appearance of at least one sign of skin aging. Topical use of the composition can increase the levels of hyaluronic acid in a direction seen in younger skin, thereby reducing the appearance of signs of skin aging by providing structural support to the skin.

[0051] The compositions of the invention are also suitable for reducing hyperkeratinization of the epidermis, and therefore can be used for the treatment or prevention of conditions characterized by hyperkeratinization, such as acne or warts.

[0052] The compositions are also suitable for treating or preventing such skin conditions as cutis laxa (elastin-related disorder), sclerosis / scleroderma (collagen-related disorder), keratosis pilaris, cellulite, stretch marks, psoriasis, warts, Kaposi's sarcoma, and cutaneous T-cell lymphoma.

[0053] The compositions of the present invention are also suitable for application to oral mucosa. The compositions can be applied to oral mucosa requiring increased mucin induction, increased hyaluronic acid induction, improved barrier, or improved tight junctions.

[0054] The compositions are further suitable for the treatment or prevention of asthma, allergies, and itch. For example, the compositions can be applied topically to the skin or intranasally to the nasal mucosa for such purposes.

[0055] plant extract The present inventors have unexpectedly identified plant extracts having retinol-like bioactivity, the extracts being obtained from plants including, for example, plants of the Acronythia, Licoricea, Calendula, and Trefoil genera.

[0056] Examples of plants of the genus Acronychia include Acronychia aberrans, Acronychia acidula, Acronychia acronychioides, Acronychia acuminate, Acronychia baeuerlenii, Acronychia chooreechillum, Acronychia crassipetala, Acronychia eungellensis, Acronychia imperforate, Acronychia laevis, Acronychia laurifolia, Acronychia laurifolia, Acronychia littoralis, Acronychia oblongifolia, Acronychia octandra, Acronychia parviflora, Acronychia pauciflora, Acronychia pedunculata, Acronychia pubescens, Acronychia species (Batavia dauns), Acronychia suberosa, Acronychia vestita, and Acronychia wilcoxiana.

[0057] In one embodiment, the extract is obtained from Acronychia acidula. The common names of Acronychia acidula are lemon aspen, hard aspen, and lemonwood. The Latin synonymous names of Acronychia acidula are Jambolifera acidula and Acronychia superba.

[0058] Examples of plants in the genus Licaria include Licaria vernicosa, Licaria brittoniana, Licaria canella, Licaria cubensis, Licaria velutina, and Licaria triandra. There are about 40 reported species of the genus Licaria, which are endemic to Central and South America.

[0059] In one embodiment, the extract is obtained from Licaria bernicosa.

[0060] The Calendula genus includes 15 to 20 species, such as Calendula officinalis. Known synonyms of Calendula include Calendula aurantiaca, Calendula eriocarpa, Calendula hydruntina, Calendula prolifera, Calendula × santamariae, and Calendula officinalis.

[0061] In one embodiment, the extract is obtained from Calendula officinalis, whose common names are pot marigold, calendula officinalis, common marigold, and scotch marigold.

[0062] There are 36 known species of Trigonella, including fenugreek, Trigonella balansae, Trigonella corniculata, Trigonella maritima, Trigonella spicata, Trigonella caerulea, Trigonella occulta, Trigonella polycerata, Trigonella Calliceras, and Trigonella Cretica. Fenugreek, or the herb fenugreek, is the best known Trigonella species.

[0063] In one embodiment, the extract is obtained from fenugreek, whose common names are fenugreek, Greek hay, Greek clover, bird's foot, fenugrec, hu lu ba, oleander, and bockshornklee.

[0064] Any of the various extracts of Acronythia, Licorice, Calendula, or Reylonia can be used. One extract or a combination of extracts can be used.

[0065] The extract can be obtained from any part of the plant, such as the fruit, seeds, bark, leaves, flowers, petals, roots and wood, in certain embodiments, the extract is obtained from the fruit, wood, petals or leaves of the plant.

[0066] In one embodiment, the extract is from the fruit of Acronitia acidula.

[0067] In another embodiment, the extract is from the xylem of Licaria bernicosa.

[0068] In a further embodiment, the extract is from the root of Licoricelia bernicosa.

[0069] In another embodiment, the extract is from calendula petals.

[0070] In another embodiment, the extract is from fenugreek leaves.

[0071] In certain embodiments, the Acronitia and / or Likaria extracts useful in the present invention comprise a compound of the following formula:

[0072] [ka] During the ceremony, R1 is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 selected from the group consisting of alkynyl, and C3-C8 cycloalkyl or aryl; R2 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl or aryl, -OC1-C6 alkyl, -OC2-C6 alkenyl, -OC2-C6 alkynyl, -OC3-C8 cycloalkyl or aryl, thiol, -SC1-C6 alkyl, -SC2-C6 alkenyl, -SC2-C6 alkynyl, -SC3-C8 cycloalkyl or aryl, -NR4C1-C6 alkyl, -NR4C2-C6 alkenyl, -NR4C2-C6 alkynyl, and -NR4C3-C8 cycloalkyl or aryl; R3 is selected from -CO2H, -CO2R4, or an isosteric equivalent of a carboxy group, and R4 is C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, or aryl; Y is -(CH2-CH2)-, -(CH=CH)-, or

[0073] [ka] and or a cosmetically acceptable salt thereof.

[0074] In a particular embodiment, the Acronitia and / or Likaria extract useful in the present invention comprises the following formula:

[0075] [ka] During the ceremony, R1 is C5~C 16 Alkyl, C5-C 16 Alkenyl, and C5-C 16 Alkynyl, more preferably C5-C, including, for example, farnesyl. 16 alkenyl, R2 is selected from the group consisting of hydrogen, hydroxyl, -OC1-C6 alkyl, -OC2-C6 alkenyl, -OC2-C6 alkynyl, -OC3-C8 cycloalkyl, more preferably hydrogen, hydroxyl, -OC1-C6 alkyl, even more preferably hydrogen or -OC1-C3 alkyl; R3 is selected from -CO2H, -CO2R4, and R4 is selected from a C1-C6 alkyl, or an isosteric equivalent of a carboxy group; Y is -(CH-CH)- or -(CH=CH)-; or a cosmetically acceptable salt thereof.

[0076] In certain embodiments, at least one of the compounds of the formula above is present in an extract of Acronitia and / or Likaria at a concentration of greater than or equal to 1% (or about 1%) to about 20%, or optionally from about 7% (or about 7%) to about 10% (or about 10%) by weight of the extract of Acronitia and / or Likaria.

[0077] In certain embodiments, the compound of the above formula is in the form of an acid or alkyl ester selected from (or selected from the group consisting of) 3-(4-farnesyloxyphenyl)-propionic acid, 3-(4-farnesyloxy-3-hydroxyphenyl)-propionic acid, 3-(4-farnesyloxy-3-methoxyphenyl)-propionic acid, alkyl esters thereof, in particular ethyl esters thereof, and combinations of two or more thereof.

[0078] In certain embodiments, the compound of the above formula is 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester.

[0079] In certain embodiments, 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester is present in the extract of Acronychia and / or Likaria at a concentration of greater than or equal to 1% (or about 1%) to about 20%, or optionally from about 7% (or about 7%) to about 10% (or about 10%) by weight of the extract of Acronychia and / or Likaria.

[0080] 3-(4-Farnesyloxyphenyl)-propionic acid and / or its ethyl ester can be synthesized using conventional organic synthesis processes.

[0081] Thus, in one embodiment, a composition comprising 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester is used. Such a composition can be used in any of the methods of the present invention. In certain embodiments, the composition may comprise 1 wt.% or more (or about 1 wt.%) to about 20 wt.%, or optionally about 7 wt.% (or about 7 wt.%) to about 10 wt.% (or about 10 wt.%) of 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester, based on the total weight of the composition.

[0082] Suitable extracts can be obtained using conventional methods including, but not limited to, grinding, macerating, pressing, squeezing, grinding, centrifugation, and / or cold irrigation, stirring / distillation, microwave assisted extraction, supercritical / subcritical CO2 compressed gas extraction, pressurized solvent extraction, accelerated solvent extraction, pressurized or regular hot water extraction, surfactant assisted heated hot water extraction, oil extraction, membrane extraction, Soxhlet extraction, gold finger distillation / extraction, and / or direct extraction of materials from the biomass, for example, by the processes disclosed in U.S. Pat. Nos. 7,442,391, 7,473,435, and 7,537,791, Integrated Botanical Technologies, LLC, which are incorporated herein by reference, or by other methods such as solvent extraction.

[0083] Any of a variety of solvents, including polar solvents, non-polar solvents, or combinations of two or more thereof, can be used in methods involving solvent extraction. Suitable polar solvents include polar inorganic solvents such as water, polar organic solvents such as alcohols and corresponding organic acids, e.g., C1-C8 alcohols including methanol, ethanol, propanol, butanol, etc., and organic acids including acetic acid, formic acid, propanoic acid, etc., polyols and glycols including C1-C8 polyols / glycols, etc., and combinations of two or more thereof. Suitable non-polar solvents include non-polar organic solvents such as alkanes including C1-C8 alkanes, cycloalkanes including C1-C8 alkanes, alkyl ethers including C1-C8 alkyl ethers, petroleum ethers, ketones including C1-C8 ketones, ketones including methylene chloride, ethyl acetate, xylene, toluene, chloroform, vegetable oils, mineral oils, etc. In another embodiment, the extraction may be obtained by supercritical fluid extraction with or without the non-polar solvents mentioned above or polar modifiers such as C1-C8 alcohols, water, C1-C8 polyols / glycols or C1-C8 organic acids.

[0084] In one embodiment, the extract comprises an extract of Acronychia acidula. In another embodiment, the extract of the present invention comprises a combination of a polar extract and a non-polar extract of the fruit of Acronychia acidula. In another embodiment, the extract of the present invention comprises an alcoholic or glycolic extract of the fruit of Acronychia acidula.

[0085] In one embodiment, the extract comprises an extract of Licaria bernicosa. In another embodiment, the extract of the present invention comprises a combination of polar and non-polar extracts of Licaria bernicosa xylem or Licaria bernicosa root. In another embodiment, the extract of the present invention comprises an alcoholic extract of Licaria bernicosa tree or Licaria bernicosa root.

[0086] In another embodiment, the extract is a polar extract prepared using a polar solvent comprising water, a C1-C8 alcohol, a C1-C8 polyol, or a C1-C8 glycol, or a combination of two or more thereof. In certain embodiments, the extract is extracted using one or more C1-C4 alcohols, C1-C4 polyols, and / or C1-C4 glycols. In certain embodiments, the extract is prepared using a solvent comprising methanol, ethanol, or a combination thereof in the presence or absence of water.

[0087] In another embodiment, the extract is a polar extract extracted from the fruit of Acronychia acidula using a combination of alcohol and water.

[0088] In yet another embodiment, the extract is a polar extract extracted from the crushed xylem of Licaria bernicosa or the crushed roots of Licaria bernicosa using methanol.

[0089] In one embodiment, the extract comprises an extract of Calendula officinalis. In another embodiment, the extract of the present invention comprises a combination of a polar extract and a non-polar extract of Calendula officinalis petals. In another embodiment, the extract of the present invention comprises a non-polar extract of Calendula officinalis petals.

[0090] In one embodiment, the extract comprises an extract of fenugreek. In another embodiment, the extract of the present invention comprises a combination of polar and non-polar extracts of fenugreek leaves. In another embodiment, the extract of the present invention comprises a non-polar extract of fenugreek leaves.

[0091] In yet another embodiment, the extract is a non-polar extract prepared using a non-polar solvent comprising one or more of C1-C8 alkanes, C1-C8 cycloalkanes, C1-C8 alkyl ethers, C1-C8 alkyl esters and / or chloroform, more preferably one or more of C1-C8 alkanes, C1-C8 alkyl esters and / or chloroform.

[0092] In yet another embodiment, the extract is a non-polar extract prepared using hexane, ethyl acetate, chloroform, or a mixture of two or more thereof, hi yet another embodiment, the extract is a non-polar extract prepared using ethyl acetate.

[0093] In one embodiment, the plant extract may be obtained by extracting cell cultures of various plants, including cell cultures of the genera Acronychia, Licaria, Calendula and / or Trefoil. The cell cultures extracted to obtain the plant extracts used in the present invention may be in any form, including suspension cell cultures, etc.

[0094] bacterial extract The present inventors have unexpectedly identified a bacterial extract with retinol-like bioactivity. Actinomyces bacteria include many species that have been fully characterized, as well as some species that are not fully characterized, such as one species collected from the United States and labeled as A5640. Samples of the bacteria are collected, grown in culture, and made into extracts. The extracts are currently part of a natural product collection under the care of the Baruch S. Blumerg Institute, Doylestown, PA (formerly known as the Institute of Hepatitis Virus Research Labs (IHVR)). In one embodiment, the extract is obtained from an Actinomyces species that has the ability to produce a chemical composition similar to that produced by the extract A5640. In another embodiment, the bacteria is collected in the United States, and the strain is identical to the previously assigned species A5640.

[0095] composition In one embodiment, the method of the present invention comprises applying a composition comprising a plant or bacterial extract as described herein to a tissue in need of treatment. Such tissue may be, for example, human skin, hair, nails, oral mucosa, nasal mucosa, or vaginal mucosa. Such tissue may require treatment or prevention of a disease or condition treatable or preventable by a retinoid, preferably retinol.

[0096] Preferably, the method of the present invention comprises administering to the tissue in need of treatment a safe and effective amount of a composition comprising an extract of the present invention. In the case of skin in need of anti-aging treatment, an anti-aging effective amount of such extract can be used.

[0097] In one embodiment, the method comprises applying to the tissue in need from greater than 0% to about 20% by weight of the extract based on the total weight of the composition. In another embodiment, the method comprises applying to the tissue in need from about 0.0001% to about 20% by weight, or from about 0.001% to about 10% by weight, or from about 0.01% to about 5% by weight, or from about 0.1% to about 5% by weight, or from about 0.2% to about 2% by weight of the extract based on the total weight of the composition. In yet another embodiment, the method comprises applying to the tissue in need from greater than 0% to about 1% by weight, or from about 0.0001% to about 1% by weight, or from about 0.001% to about 1% by weight, or from about 0.01% to about 1% by weight of the extract based on the total weight of the composition.

[0098] Any suitable carrier can be used depending on the route of administration, i.e. topical, oral, buccal, intranasal, periodontal, or vaginal.Preferably, in topical compositions, the carrier is a cosmetically acceptable carrier.As will be appreciated by those skilled in the art, a cosmetically acceptable carrier is a carrier suitable for use in contact with the body, for example, in contact with the skin, hair, or nails, without excessive toxicity, incompatibility, instability, irritation, allergic reaction, etc.

[0099] A safe and effective amount of carrier is used in the composition. For example, the carrier is about 50% to about 99.999%, preferably about 80% to about 99.9%, more preferably about 99.9% to about 95%, and most preferably about 99.8% to about 98% of the composition. The carrier may be in a wide variety of forms. For example, emulsion carriers are useful herein, including but not limited to oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions. These emulsions may cover a wide range of viscosities, for example, from about 100 cP to about 200,000 cP.

[0100] Examples of suitable cosmetically acceptable carriers include cosmetically acceptable solvents and materials for cosmetic solutions, suspensions, lotions, creams, serums, essences, gels, toners, sticks, sprays, ointments, cleaning solutions and bars, shampoos, hair conditioners, pastes, foams, mousses, powders, shaving creams, wipes, patches, strips, powered patches, microneedle patches, bandages, hydrogels, film-forming products, facial and skin masks, make-up, liquid drops, etc. These product types may contain several types of cosmetically acceptable carriers, including, but not limited to, solutions, suspensions, emulsions such as microemulsions and nanoemulsions, gels, solids, liposomes, other encapsulation techniques, etc.

[0101] The following are non-limiting examples of such carriers. Other carriers may also be formulated by those skilled in the art. In one embodiment, the carrier comprises water. In a further embodiment, the carrier may further comprise one or more aqueous or organic solvents. Examples of organic solvents include, but are not limited to, dimethyl isosorbide, isopropyl myristate, cationic, anionic, and nonionic surfactants, vegetable oils, mineral oils, waxes, gums, synthetic and natural gelling agents, alkanols, glycols, and polyols. Examples of glycols include, but are not limited to, glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, capryl glycol, glycerol, butanediol, and hexanetriol, and copolymers or mixtures thereof. Examples of alkanols include, but are not limited to, those having from about 2 carbon atoms to about 12 carbon atoms (e.g., from about 2 carbon atoms to about 4 carbon atoms), such as isopropanol and ethanol. Examples of polyols include, but are not limited to, those having from about 2 carbon atoms to about 15 carbon atoms (e.g., from about 2 carbon atoms to about 10 carbon atoms), such as propylene glycol. The organic solvent may be present in the carrier in an amount of from about 1 percent to about 99.99 percent (e.g., from about 20 percent to about 50 percent) based on the total weight of the carrier. Water may be present in the carrier in an amount of from about 5% to about 95% (e.g., from about 50% to about 90%) based on the total weight of the carrier (prior to use). The solution may contain any suitable amount of solvent, including from about 40% to about 99.99%. In one embodiment, the solution contains from about 50% to about 99.9%, from about 60% to about 99%, from about 70% to about 99%, from about 80% to about 99%, or from about 90% to about 99%.

[0102] A lotion may be made from such a solution. A lotion typically contains at least one emollient in addition to a solvent. A lotion may contain about 1% to about 20% (e.g., about 5% to about 10%) of an emollient and about 50% to about 90% (e.g., about 60% to about 80%) of water. As used herein, "emollient" refers to a material used to prevent or reduce dryness and to protect the skin or hair. Examples of emollients include, but are not limited to, those listed in the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen, pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and Fragrance Assoc, Washington, DC, 7th Edition, 1997) (hereinafter, "ICI Handbook").

[0103] Another type of product that can be formulated from a solution is a cream, which typically contains about 5% to about 50% (e.g., about 10% to about 20%) of emollient(s) and about 45% to about 85% (e.g., about 50% to about 75%) water.

[0104] Yet another type of product that can be formulated from a solution is an ointment. An ointment may contain a simple base of animal, vegetable, or synthetic oils, or semi-solid hydrocarbons. An ointment may contain from about 2% to about 10% of an emollient(s) and from about 0.1% to about 2% of a thickening agent(s).

[0105] The compositions useful in the present invention can also be formulated as emulsions. When the carrier is an emulsion, about 1% to about 10% (e.g., about 2% to about 5%) of the carrier contains an emulsifier. The emulsifier may be nonionic, anionic, or cationic. Examples of emulsifiers include, but are not limited to, those described in the ICI Handbook, pp. 1673-1686.

[0106] Lotions and creams can be formulated as emulsions. Typically, such lotions contain 0.5% to about 5% emulsifier, and such creams typically contain about 1% to about 20% (e.g., about 5% to about 10%) emollient. They contain about 20% to about 80% (e.g., about 30% to about 70%) water and about 1% to about 10% (e.g., about 2% to about 5%) emulsifier(s).

[0107] Single-phase emulsion skin care formulations, such as lotions and creams, of the oil-in-water and water-in-oil types, are well known in the art and are useful in the present invention.Multiple-phase emulsion compositions, such as water-in-oil-in-water or oil-in-water-in-oil types, are also useful in the present invention.In general, such single-phase or multi-phase emulsions contain water, emollients, and emulsifiers as essential ingredients.

[0108] The compositions of the present invention can also be formulated as gels (e.g., aqueous, alcohol, alcohol / water, or oil gels using a suitable gelling agent). Suitable gelling agents for aqueous and / or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethylcellulose and hydroxypropylcellulose). Suitable gelling agents for oils (such as mineral oil) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain about 0.1% to 5% by weight of such gelling agents.

[0109] The compositions of the present invention can also be formulated into solid formulations (e.g., wax-based sticks, soap bars, powders, or wipes). The compositions of the present invention can also be combined with solid, semi-solid, or soluble substrates (e.g., wipes, masks, pads, gloves, or strips).

[0110] The compositions of the present invention may further comprise one or more additional cosmetically active agents. As used herein, a "cosmetic active agent" is a compound that has a cosmetic or therapeutic effect on human tissue, such as the skin, hair, nails, or mucous membranes. Examples of suitable additional cosmetic active agents include skin lightening agents, darkening agents, anti-acne agents, shine adjusting agents, antimicrobial agents such as anti-yeast, anti-fungal and anti-bacterial agents, anti-inflammatory agents, anti-parasitic agents, topical analgesics, sunscreens, photoprotectants, antioxidants, keratolytic agents, detergents / surfactants, moisturizers, nutrients, vitamins, energy enhancers, antiperspirants, skin astringents, deodorants, hair removal agents, hair growth enhancers, hair growth retarders, stabilizers, hydration enhancers, efficacy enhancers, anti-calluses agents, skin conditioning agents, anti-cellulite agents, fluorides, tooth whitening agents, anti-tartar agents and tartar dissolving agents, malodor control agents such as malodor masking agents or pH altering agents, and the like.

[0111] Examples of various suitable additional cosmetically acceptable actives include, but are not limited to, hydroxy acids, benzoyl peroxide, D-panthenol, UV filters, such as, but not limited to, avobenzone (Parsol 1789), bisdisulizole disodium (Neo Heliopan AP), diethylaminohydroxybenzoyl hexyl benzoate (Uvinul A Plus), ecamsule (Mexoryl SX), methyl anthranilate, 4-aminobenzoic acid (PABA), cinoxate, ethylhexyl triazone (Uvinul T150), homosalate, 4-methylbenzylidene camphor (Parsol 5000), octyl methoxycinnamate (Octinoxate), octyl salicylate (Octisalate), padimate O (Escalol 507), phenylbenzimidazole sulfonic acid (Ensulizole), polysilicone-15 (Parsol SLX), Trolamine Salicylate, Bemotrizinol (Tinosorb S), Benzophenone 1-12, Dioxybenzone, Drometrizole Trisiloxane (Mexoryl XL), Isocotridinol (Uvasorb HEB), Octocrylene, Oxybenzone (Eusolex 4360), Sulisobenzone, Bisoctrizol (Tinosorb M), titanium dioxide, zinc oxide, carotenoids, free radical scavengers, spin traps, retinoids and retinoid precursors such as retinol, retinoic acid and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogen, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper chloride, Cu:Gly-His-Lys, peptides, sugar amines, coenzyme Q10, amino acids such as proline, vitamins, lactobionic acid, acetyl coenzyme A, niacin, riboflavin, thiamine, ribose, electron transporters such as NADH and FADH2, and other plant extracts such as oat, aloe vera, feverfew, soybean, shiitake mushroom extracts, and derivatives and mixtures thereof.

[0112] In one embodiment, the composition of the present invention is a skin care composition comprising a plant or bacterial extract as described herein and at least one skin lightening active. Examples of suitable skin lightening actives include, but are not limited to, tyrosinase inhibitors, melanin inhibitors, melanosome transfer inhibitors including PAR-2 ​​antagonists, exfoliants, sunscreens, retinoids, antioxidants, tranexamic acid, skin whitening agents, allantoin, opacifiers, talc and silica, zinc salts, and the like, as well as other agents as described in Solano et al. Pigment Cell Res. 2006, 19(550-571). Examples of suitable tyrosinase inhibitors include, but are not limited to, vitamin C and its derivatives, vitamin E and its derivatives, kojic acid, arbutin, resorcinol, hydroquinone, flavones (e.g., licorice flavanoids, licorice root extract, mulberry root extract, Dioscorea Coposita root extract, Saxifragaceae extract, etc.), ellagic acid, salicylates and derivatives, glucosamine and derivatives, fullerenes, hinokitiol, diacids, acetylglucosamine, magnolignans, combinations of two or more thereof, etc. Examples of derivatives of vitamin C include, but are not limited to, ascorbic acid and its salts, ascorbic acid-2-glucoside, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and natural extracts enriched with vitamin C. Examples of derivatives of vitamin E include, but are not limited to, α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, and mixtures thereof, tocopherol acetate, tocopherol phosphate, and natural extracts enriched with vitamin E derivatives.Examples of resorcinol derivatives include, but are not limited to, resorcinol, 4-substituted resorcinols, such as 4-butylresorcinol (rucinol), 4-hexylresorcinol, phenylethylresorcinol, 4-alkylresorcinols such as 1-(2,4-dihydroxyphenyl)-3-(2,4-dimethoxy-3-methylphenyl)-propane, and natural extracts rich in resorcinol. Examples of salicylates include, but are not limited to, salicylic acid, acetylsalicylic acid, 4-methoxysalicylic acid, and salts thereof. In certain embodiments, the tyrosinase inhibitor includes 4-substituted resorcinols, vitamin C derivatives, or vitamin E derivatives. In yet another embodiment, the tyrosinase inhibitor includes phenylethylresorcinol, 4-hexylresorcinol, or ascorbyl-2-glucoside.

[0113] Examples of suitable melanin degraders include, but are not limited to, peroxides and enzymes (e.g., peroxidase and ligninase). In certain embodiments, melanin inhibitors include peroxides and ligninase.

[0114] Examples of suitable melanosome transfer inhibitors include PAR-2 ​​antagonists (e.g., soybean trypsin inhibitor or Bowman-Birk inhibitor), vitamin B3 and derivatives (e.g., niacinamide), essential soybean, whole soybean, soybean extract. In certain embodiments, the melanosome transfer inhibitor includes soybean extract or niacinamide.

[0115] Examples of exfoliants include, but are not limited to, alpha-hydroxy acids (e.g., lactic acid, glycolic acid, malic acid, tartaric acid, citric acid, or any combination of any of the foregoing), beta-hydroxy acids (e.g., salicylic acid, polyhydroxy acids such as lactobionic acid and gluconic acid), and mechanical exfoliants (e.g., microdermabrasions). In certain embodiments, the exfoliant includes glycolic acid or salicylic acid.

[0116] Examples of sunscreens include avobenzone (Parsol 1789), bisdisulizole disodium (Neo Heliopan AP), diethylaminohydroxybenzoylhexylbenzoate (Uvinul A Plus), ecamsule (Mexoryl SX), methyl anthranilate, 4-aminobenzoic acid (PABA), cinoxate, ethylhexyl triazone (Uvinul T150), homosalate, 4-methylbenzylidene camphor (Parsol 5000), octyl methoxycinnamate (Octinoxate), octyl salicylate (Octisalate), padimate O (Escalol 507), phenylbenzimidazole sulfonic acid (Ensulizole), polysilicone-15 (Parsol SLX), trolamine salicylate, and bemotrizinol (Tinosorb S), Benzophenone 1-12, Dioxybenzone, Drometrizole Trisiloxane (Mexoryl XL), Iscotrizinol (Uvasorb HEB), Octocrylene, Oxybenzone (Eusolex 4360), Sulisobenzone, Bisoctrizole (Tinosorb M), Titanium Dioxide, Zinc Oxide and the like.

[0117] Examples of retinoids include, but are not limited to, retinol, retinaldehyde, retinoic acid, retinyl palmitate, isotretinoin, tazarotene, bexarotene, and adapalene. In certain embodiments, the retinoid is retinol.

[0118] Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine, glutathione), lipoic acid and dihydrolipoic acid, stilbenoids (e.g., resveratrol and derivatives), lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl-2-glucoside, ascorbyl palmitate and ascorbyl polypeptide). Suitable oil-soluble antioxidants for use in the compositions of the present invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiquinone. Suitable natural extracts containing antioxidants for use in the compositions of the present invention include, but are not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (e.g., genistein and daidzein), extracts containing resveratrol, and the like. Examples of such natural extracts include grape seed, green tea, pine bark, feverfew, parthenolide-free feverfew, oat extract, grapefruit extract, wheat germ extract, hesperidin, grape extract, purslane extract, licochalcone, chalcone, 2,2'-dihydroxychalcone, primrose extract, propolis, and the like.

[0119] Examples of vitamins include, but are not limited to, vitamin A, B vitamins (eg, vitamin B3, vitamin B5, and vitamin B12), vitamin C, vitamin K, and vitamin E, and derivatives.

[0120] The additional cosmetic active agent may be present in the composition in any suitable amount, such as from about 0.0001% to about 20% by weight of the composition, such as from about 0.001% to about 10% by weight, such as from about 0.01% to about 5% by weight, etc. In certain embodiments, in an amount of 0.1% to 5%, and in other embodiments, from 1% to 2%.

[0121] A variety of other materials may be present in the compositions of the present invention, including, for example, chelating agents, moisturizing agents, proteins, opacifiers, conditioners, preservatives, fragrances, etc. The compositions may include a surfactant, such as one selected from the group consisting of anionic, nonionic, amphoteric, cationic, or a combination of two or more thereof.

[0122] Compositions and products containing such compositions of the present invention can be prepared using methods well known to those skilled in the art.

[0123] In certain embodiments, the present invention includes applying the compound or composition of the present invention through a substrate that includes such material.Any suitable substrate can be used in the present invention.Examples of suitable substrates and substrate materials are disclosed, for example, in U.S. Patent No. 7,452,547 and U.S. Patent Application Publication No. 2009 / 0241242, which are incorporated herein by reference in their entirety.

[0124] In one embodiment, the substrate is a wipe or facial mask. Such embodiments include the water-soluble substrate as defined in the references cited above. In certain embodiments, the water-soluble substrate can have a size and shape that covers the face of a human user to facilitate placement of the water-soluble substrate as a mask substrate around the face of the user. For example, the water-soluble mask substrate can have openings for the mouth, nose, and / or eyes of the user. Alternatively, the water-soluble substrate can be free of such openings. Such configurations without openings can be useful in embodiments of the invention where the water-soluble substrate is to be placed over non-facial parts of the skin or where the water-soluble substrate is intended to be used as a wipe. The water-soluble substrate can have a variety of shapes, such as angular shapes (e.g., rectangular) or arcuate shapes, such as circular or elliptical.

[0125] In one embodiment, the product comprises a plurality of water-soluble substrates of various shapes. In one embodiment of the present invention, the product comprises a first water-insoluble substrate and a second water-insoluble substrate. The first water-insoluble substrate is configured to be applied to the forehead and the second water-insoluble substrate is configured to be applied proximate to the mouth, such as to the lips, chin, and / or areas above and / or below the cheeks. In one embodiment of the present invention, the first water-insoluble substrate is also applied to the nose area of ​​the face. The first water-insoluble substrate is configured to be applied to the forehead and / or the cheeks near the mouth, such as the lips, chin, and / or areas above and / or below the cheeks. In one embodiment of the present invention, the first water-insoluble substrate is also applied to the nose area of ​​the face. The first water-insoluble substrate is configured to be applied to the forehead and / or the cheeks near the mouth, such as the lips, chin, and / or cheeks near the nose area. In one embodiment of the present invention, the first water-insoluble substrate is configured to be applied to the nose area of ​​the face ... 2 ~about 200cm 2 , for example, about 120 cm 2 ~Approx. 160cm 2 and the second water-insoluble substrate may have a surface area of ​​about 100 cm 2 ~about 300cm 2 , for example, about 150 cm 2 ~about 250cm 2 In one embodiment, the water-insoluble substrate has a low stiffness, for example, so that it can easily cover or conform to the face or other body part of a user.

[0126] The present invention may include application to any skin in the human body that requires treatment. For example, it may be applied to any one or more of the skin of the face, neck, chest, back, arms, armpits, hands, and / or feet. In certain embodiments, the method includes applying the plant or bacterial extract described herein to facial skin.

[0127] Additionally, the composition may be applied to other tissues including hair, nails, oral mucosa, nasal mucosa, or vaginal mucosa.

[0128] Any suitable method of applying the composition to tissue in need can be used according to the present invention.For example, the composition can be applied directly from a package to skin in need, can be applied by hand to tissue in need, or can be transferred from a substrate such as a wipe or mask, or a combination of two or more of these.In another embodiment, the composition can be applied via a dropper, tube, roller, spray, patch, or can be added to a bath or otherwise water for application to tissue, etc.

[0129] In certain embodiments, the method further comprises contacting the composition with the tissue for a period of time. For example, the composition is allowed to contact the tissue for about 15 minutes or more. In another embodiment, the composition is allowed to contact the tissue for about 20 minutes or more, more preferably about 1 hour or more.

[0130] In certain embodiments, the methods of the present invention include a regimen that involves applying the composition to the tissue multiple times over a selected period of time.

[0131] For example, the present invention provides a method of treating signs of cutaneous aging comprising applying a composition comprising an extract as described herein once or twice daily to skin in need of such treatment for at least 12 weeks, preferably at least 8 weeks, more preferably at least 2 weeks.

[0132] In certain embodiments, the method of the present invention comprises applying at least two different compositions or products comprising a plant or bacterial extract to a tissue. For example, the method can comprise applying a first composition comprising the extract to the tissue in need of treatment, followed by applying a second composition comprising the same or different extract to the skin in need of treatment. In certain embodiments, the first and second compositions can be independently selected from the group consisting of lotions, cleansers, masks, wipes, creams, serums, gels, and the like. In certain embodiments, at least one of the first and second compositions is a cleanser, lotion, cream, essence, or serum, and the other is a facial mask or wipe. In certain other embodiments, at least one of the first and second compositions is a cleanser, and the other is a lotion or cream.

[0133] In certain other embodiments, the method comprises applying to the tissue in need of treatment at least three products or compositions comprising the extract, preferably such three products are selected from the group consisting of a cleanser, a lotion, a cream, an essence, and a face mask.

[0134] The compositions of the present invention can also be formulated into ingestible compositions. As used herein, "ingestible composition" refers to a composition that is intended to be ingested or administered orally. Examples of ingestible composition forms include, but are not limited to, tablets, pills, capsules, powders, granules, solutions or suspensions, and drops. Such compositions may be swallowed whole or in chewable form. "Ingestible compositions" may also be in the form of confectionery or food products, such as cookies, candies, food bars, chewing gum, yogurt additives, sprinkles, tea, juice or other beverages, liquid shakes, etc. Ingestible compositions do not include compositions that are intended to be administered topically to the skin or oral / vaginal cavity.

[0135] The compositions can be used to treat a variety of skin diseases and conditions, such as reducing the appearance of skin aging, skin inflammation, and skin pigmentation.

[0136] Examples of skin aging that can be treated by topical or oral use of the composition of the present invention include, but are not limited to, wrinkles of the skin, loss of skin firmness or elasticity, sagging, looseness and loose tissue.As used herein, the term "wrinkles" includes fine lines, fine lines, coarse lines, cellulite, scars and stretch marks.Examples of wrinkles include, but are not limited to, fine lines around the eyes (e.g., "crow's feet"), wrinkles on the forehead and cheeks, fine lines between the eyebrows and laugh lines around the mouth.

[0137] Examples of skin inflammation that may be treated by topical or oral use of the compositions of the present invention include, but are not limited to, arthritis, contact dermatitis, atopic dermatitis, psoriasis, seborrheic dermatitis, eczema, allergic dermatitis, polymorphous light eruption, inflammatory skin diseases, folliculitis, alopecia, poison ivy dermatitis, insect bites, irritation induced by external factors including, but not limited to, chemicals, trauma, pollutants (e.g., cigarette smoke), and exposure to UV or wind, as well as secondary conditions resulting from inflammation including, but not limited to, xerosis, excess sebum, pruritus, post-inflammatory hyperpigmentation, scarring, etc.

[0138] Examples of skin pigmentation that can be treated by topical or oral use of the composition of the present invention include, but are not limited to, skin hyperpigmentation, light areas of skin, uneven skin tone, discoloration and swelling around the eyes.Discoloration and swelling around the eyes include, but are not limited to, dark circles and blackheads under the eyes.In one embodiment, the dark circles under the eyes that are treated are the result of increased blood concentration in the skin under the eyes.

[0139] Topical uses of compositions comprising the plant or bacterial extracts described herein and a cosmetically acceptable carrier include, for example, the treatment of aging of human skin, dry skin, pigmentation defects, UV damage on the skin, skin unevenness such as wrinkles, fine lines, rough or cratered skin, and disorders associated with skin aging such as defective keratinization, acne, eczema, inflammation, and skin atrophy.

[0140] As used herein, "topical use" or "topically applied" means to apply or spread directly onto the skin, hair, or nails, for example, by using the hands or an applicator such as a wipe.

[0141] In one embodiment, the present invention is a method of treating the signs of skin aging comprising topically applying to skin in need of such treatment a safe and effective amount of a composition comprising an extract as described herein.

[0142] In another embodiment, the present invention is a method for improving skin barrier properties comprising topically applying a composition comprising an extract as described herein to skin in need of improved skin barrier function and moisturization.

[0143] In another embodiment, the present invention is a method of treating acne comprising topically applying to skin in need of acne treatment a composition comprising an extract as described herein. EXAMPLES

[0144] The following materials and test methods were used in the examples.

[0145] Gene Expression Testing Methods Abdominal skin samples were obtained from human adults undergoing abdominoplasty. Informed consent was obtained from each patient and all experimental procedures were approved by the Institutional Review Board (IRB). Subcutaneous fat was carefully removed and 0.93 cm 2 Skin biopsies were prepared under sterile conditions and conditioned overnight in DMEM / F12 (1:1) medium, 2% heat-inactivated fetal bovine serum, 10 μg / mL insulin, 10 ng / mL hydrocortisone, 10 ng / mL EGF, 1xABAM in a humidified atmosphere of 5% CO2. Skin explants were treated topically for 48 hours with various concentrations. At the end of the 48 hour incubation, half of the skin biopsies were lysed in 400 μL of lysis buffer containing 100 parts RLT buffer (RNeasy Mini kit, Qiagen, Valencia, CA) to 1 part 2-mercaptoethanol in reinforced tubes with screw caps and O-ring closures, and the tissue was ground with ceramic beads (trade name PRECELLYS CKMix50-R, sold by Bertin Corp, Rockville, MD) in the tube. The tubes were shaken at 6300 rpm for 40 seconds. RNA was extracted from the solution using an RNeasy Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions, and RNA was eluted in 25 μL of RNase-free water.

[0146] Reverse transcription (RT) was performed using the Applied Biosystems High Capacity Reverse Transcription Kit (ThermoFisher Scientific, Bridgewater, NJ). Gene expression assays sold under the trade name TAQMAN for cellular retinoic acid binding protein 2 (CRABP2), heparin-binding epidermal growth factor (HbEGF), hyaluronan synthase 3 (HAS3), UDP-glucose ceramide glucosyltransferase (UGCG), polymerase (RNA) II polypeptide A (POLR2A), and master mixes sold under the trade name TAQMAN were purchased from ThermoFisher Scientific (Bridgewater, NJ). qPCR analysis was performed using TaqMan® Master Mix (ThermoFisher Scientific, Bridgewater, NJ) and run on a real-time PCR system sold under the trade name QUANTSTUDIO 7 Flex System (ThermoFisher Scientific, Bridgewater, NJ). The expression of these genes was normalized to the expression of the human POLR2A housekeeping gene. Fold changes were calculated relative to untreated or vehicle controls and a two-tailed two-sample Student's t-test (Microsoft Office Excel 2007; Microsoft, Redmond, WA, USA) was performed.

[0147] RARg Transactivation Assay Method Retinoic acid receptor gamma (RARg) agonism was assessed using the Invitrogen GeneBLAzer RAR gamma-UAS-bla HEK 293T cell line assay, in which activation of RARg leads to transcription of β-lactamase. When a FRET probe is added to the cells, FRET is observed. However, upon receptor activation and subsequent β-lactamase expression, the probe is cleaved and FRET is no longer observed.

[0148] Cells in culture are washed with PBS, trypsinized, resuspended in growth medium, and counted using a ViCell cell counter, then the appropriate amount of cells are spun down and resuspended in assay buffer (0.5E6 cells / ml). 15k cells in 30ul of assay buffer are plated into a Greiner black-walled, clear flat-bottom plate using a Combi dispenser. The last two columns are filled with assay buffer. 10ul of 4x concentrated test sample is added to the cells using a Janus dispenser, cells are spun down at 800rpm for 2 minutes without brake, left at room temperature for 15 minutes, and incubated o / n at 37°C.

[0149] After 18-20 hours of incubation, 8ul of FRET dye (Invitrogen K1096) is added using a Tempest dispenser, after which the plate is spun down for 2 minutes at 800 rpm without brake and incubated in the dark for 2 hours at room temperature. The bottom of the plate is washed using an antistatic cleaning wipe and fluorescence is measured using a BMG Pherastar plate reader (using the FRET module, 10 readings, Gain=1000 for both channels, Ex 409, Em1 460, Em2 530). The average Em1 and Em2 values ​​from assay buffer only wells are subtracted from the test Em1 and Em2 values, respectively, and subsequent determination of the Em1 / Em2 ratio represents RARg activity. Normalization was performed using DMSO and ATRA as neutral and stimulator controls, respectively.

[0150] Acronitzia acidula extract (E1) Pre-weighed frozen fruits of Acronitia acidula were homogenized in a blender for 30 seconds by adding an equal amount of denatured alcohol to the frozen fruits. The pulp was then mixed and stirred for another 24 hours at ambient temperature (22-26 °C). Additional denatured alcohol was added as necessary to keep the pulp well covered with alcohol. The mixture was then gravity filtered and the filter cake was washed with an additional amount of denatured alcohol. The entire filtrate was then dried under reduced pressure to remove the alcohol. The residue was freeze-dried to obtain a dry material free of extraction solvent and water. The extraction was repeated several times on the filter cake, and each extract regularly gave an extraction yield of 5-7%. One such batch was prepared using 100 kg of frozen fruits of Acronitia acidula, and the dried extract (E1) was used in subsequent experiments described herein.

[0151] Licorice vernicosa extract (E2, E3) Two extracts of Licaria vernicosa were obtained from the Baruch S. Blumerg Institute, Doylestown, PA (formerly known as IVHR). The first extract was from the xylem of the plant (E2) and the second extract was from the root of the plant (E3). Within the nomenclature of the IHVR collection, the extracts are labeled as IHVR_40256_G10=X-005348-001E002 and IHVR_40256_E10=X-005346-001M002, respectively. The xylem and root of Licaria vernicosa (Mez) Kosterm were collected from Guyana. 504.3 g of dried ground xylem plant material was extracted with enough methanol, which was dried in vacuum to obtain 10.54 g of crude methanol extract (E2) for X-005348-001E002. 403.8 g of dried ground root material was extracted with sufficient methanol which was dried under vacuum to give 18.11 g of crude methanol extract (E3) for X-005346-001M002.

[0152] Extract of Actinomyces sp. A5640 (E4) The general culture and extraction method for this strain is documented at the Baruch S. Blumerg Institute, Doylestown, PA (formerly known as IVHR). Within the nomenclature of the IHVR collection, the extract is labeled as IHVR_39565_F7. Extracts of Actinomyces sp. A5640 are referred to herein as E4.

[0153] Calendula extract (E5) and fenugreek extract (E6) Calendula extract (E5) and Fenugreek extract (E6) are available from Caithness Biotechnologies Ltd, UK (http: / / www.caithnessbiotechnes.com). These extracts are part of the Phytotitre Natural Product Library, available to the public for purchase. The preparation method of the extracts is described by Caithness Biotechnologies Ltd. as non-polar, using a mixture of methanol and methylene chloride. In a typical extraction, a pre-weighed amount of dry powdered biomass is suspended in a mixture of methanol / methylene chloride (1:1) and stirred overnight at ambient temperature. The suspension is then filtered and the filtrate is dried under reduced pressure to a solvent-free residue. The residue is then dissolved in a sufficient amount of 100% DMSO to obtain a stock solution at a concentration of 10 mg / mL. Such a stock solution was used to dilute in the appropriate medium for screening.

[0154] Example 1 Gene expression analysis of CRABP2 was performed on compositions of 0.1% (w / v) Acronitzia acidula extract (E1), 0.1% (w / v) Licaria vernicosa extract (E2 and E3), and 0.1% (w / v) Actinomyces sp. A5640 extract (E4) in a 30 / 70 (v / v) polypropylene glycol / ethanol vehicle, respectively. Gene expression was performed according to the Gene Expression Analysis Test Method described above. The test compositions were compared to a 0.1% retinol product sold under the trade name NEUTROGENA RAPID WRINKLE REPAIR (RWR) (Johnson & Johnson Consumer Inc., Skillman NJ), untreated, and vehicle treatment. The results are shown in Table 1.

[0155] [Table 1]

[0156] result: Cellular retinoid-binding proteins (CRABPs) are a family of cytoplasmic binding proteins that have been shown to promote retinol uptake and prevent spontaneous nonenzymatic isomerization and oxidation of retinol. CRABP2 (cellular retinoic acid-binding protein-II) message has been shown to be upregulated by treatment with retinol in human skin both in vivo and in vitro.

[0157] This example shows that topical treatment of human skin explants with a composition of Acronitzia acidula, Licaria vernicosa and Actinomyces sp. A5640 extracts used at 0.1% (w / v) induces retinol-like bioactivity as indicated by induction of gene expression of CRABP2. Thus, upregulation of CRABP2 and its associated retinol-like activity indicates retinol-like related skin benefits such as improved skin appearance including reducing signs of aging including reducing fine lines and wrinkles.

[0158] Example 2 Gene expression analysis of CRABP2 was performed with compositions of 0.04% (w / v) to 3% (w / v) Acronitzia acidula extract (E1) in a 30 / 70 (v / v) polypropylene glycol / ethanol vehicle according to the Gene Expression Analysis Test Method described above. The test compositions were compared to a 0.1% retinol product sold under the trade name NEUTROGENA RAPID WRINKLE REPAIR (RWR) and a vehicle treatment. The results are shown in Table 2.

[0159] [Table 2]

[0160] result: Cellular retinoid-binding proteins (CRABPs) are a family of cytoplasmic binding proteins that have been shown to promote retinol uptake and prevent spontaneous nonenzymatic isomerization and oxidation of retinol. CRABP2 (cellular retinoic acid-binding protein-II) message has been shown to be upregulated by treatment with retinol in human skin both in vivo and in vitro.

[0161] This example shows that topical treatment of human skin explants with a composition of Acronitzia acidula extract at 0.04% (w / v) to 3% (w / v) induced expression of the retinoic acid gene CRABP2 gene in human skin explants when applied topically. * , p<0.05. Acronitzia acidula extract induces retinol-like bioactivity, as shown by induction of CRABP2 gene expression, similar to the benchmark 0.1% RWR retinol used as the positive control in the assay.

[0162] Example 3 Gene expression analysis for HAS3, UGCG, and HbEGF was performed on a composition of 0.1% (w / v) Acronitzia acidula extract (E1) in a 30 / 70 (v / v) polypropylene glycol / ethanol vehicle according to the Gene Expression Analysis Test Method described above. The test composition was compared to a 0.1% retinol product sold under the trade name NEUTROGENA RAPID WRINKLE REPAIR (RWR), vehicle treatment, and no treatment. The results are shown in Table 3.

[0163] Upregulation of these gene activity has been shown to have retinol-like related skin benefits such as improved skin appearance including reduced signs of aging including reduced fine lines and wrinkles.Upregulation of UCGC genes increases glycosylated ceramide formation which enhances epidermal lipid production which strengthens the skin barrier.

[0164] [Table 3]

[0165] result: The genes for heparin-binding epidermal growth factor (HbEGF) and hyaluronan synthase 3 (HAS3) are also induced by retinol. HbEGF is known to improve skin thickness, plumpness and reverse skin thinning caused by steroid treatment, and HAS3 is known to improve skin hydration. UGCG is an enzyme involved in human ceramide synthesis and known to improve the skin barrier.

[0166] Example 3 shows that topical treatment of human skin explants with a composition of 0.1% (w / v) Acronitzia acidula extract induced similar induction of HAS3, HbEGF, and ceramide glucosyltransferase (UGCG) gene expression in human skin explants as RWR, 0.1% retinol when applied topically. * , p<0.05.

[0167] Example 4 Human skin explant biopsies, 10 mm biopsies, were treated topically for 7 days with either a 30 / 70 (v / v) polypropylene glycol / ethanol vehicle alone or a composition of 1% (w / v) Acronitzia acidula extract (E1) in a 30 / 70 (v / v) polypropylene glycol / ethanol vehicle to investigate the effect on elastin fiber formation. In addition, human skin explants were also treated topically with a formulation containing 0.1% retinol as a positive control. Additionally, a sample of human skin explant was left untreated as a negative control. After 7 days, skin biopsies were fixed in 10% buffered formalin solution (Thermo Fisher Scientific, Hudson, NH), dehydrated, and then embedded in paraffin. Five-micrometer-thick sections were taken from each biopsy. Sections were stained with Luna stain (American HistoLabs, Gaithersburg, MD) to document the presence of purple elastin fibers. Images of the skin explants were obtained using a Leitz microscope and a Leica camera (Leica, Allendale, NJ). Figure 1 shows images of skin explants including untreated, vehicle treated, treated with 1% Acronitzia acidula extract (E1) and treated with 1% retinol.

[0168] result: In contrast to untreated human skin samples or skin samples topically treated with 30 / 70 (v / v) polypropylene glycol / ethanol vehicle alone, an increase in elastin fiber formation was observed in the epidermal-dermal regions of human skin explants topically treated for 7 days with a composition of 1% (w / v) Acronitzia acidula extract (E1) in 30 / 70 (v / v) polypropylene glycol / ethanol vehicle, similar to that observed with a formulation containing 0.1% retinol, used as the experimental positive control.

[0169] Increased elastin formation produces skin that is stronger, more elastic, and less prone to signs and symptoms of skin aging, such as wrinkle formation. Increased formation of elastin fibers is a known retinol-induced anti-aging skin benefit associated with improved skin appearance, including reduced signs of aging, including reduced fine lines and reduced wrinkles. Thus, increased elastin fiber formation by Acronitzia acidula extract is indicative of retinol-like activity and retinol-like associated skin benefits, including reduced signs of aging, including reduced fine lines and reduced wrinkles.

[0170] Example 5 Human skin explant biopsies, 10 mm biopsies, were treated topically for 7 days with either a 30 / 70 (v / v) polypropylene glycol / ethanol vehicle alone or a composition of 1% (w / v) Acronitzia acidula extract (E1) in a 30 / 70 (v / v) polypropylene glycol / ethanol vehicle to investigate the effect on elastin fiber formation. In addition, human skin explants were also treated topically with a formulation containing 0.1% retinol as an experimental positive control for comparison purposes. Additionally, a sample of human skin explant was left untreated as an experimental negative control for comparison purposes. After 7 days, the skin biopsies were fixed in 10% buffered formalin solution (Thermo Fisher Scientific, Hudson, NH), dehydrated, and then embedded in paraffin. Five-micrometer-thick sections were taken from each biopsy. Sections were stained with Herovici stain (American HistoLabs, Gaithersburg, MD) to record blue procollagen. Images of the skin explants were obtained using a Leitz microscope and a Leica camera (Leica, Allendale, NJ). Figure 2 shows images of skin explants including untreated, vehicle treated, treated with 1% Acronitzia acidula extract (E1) and treated with 1% retinol.

[0171] result: In contrast to untreated human skin samples or skin samples topically treated with 30 / 70 (v / v) polypropylene glycol / ethanol vehicle alone, an increase in procollagen formation was observed in the epidermal-dermal region of human skin explants topically treated for 7 days with a composition of 1% (w / v) Acronitzia acidula extract (E1) in 30 / 70 (v / v) polypropylene glycol / ethanol vehicle, similar to that observed with a formulation containing 0.1% retinol, used as the experimental positive control.

[0172] Increased procollagen formation produces skin that is stronger, more elastic, and less prone to signs and symptoms of skin aging, such as wrinkle formation, improves hydration, and improves skin barrier function. Increased procollagen formation is a known retinol-induced anti-aging skin benefit associated with improved skin appearance, including reducing signs of aging, including reducing fine lines and wrinkles. Thus, increased procollagen formation by Acronisia acidula extract is retinol-like active and indicative of retinol-like related skin benefits, including reducing signs of aging, including reducing fine lines and wrinkles.

[0173] Example 6 Various extracts of Calendula officinalis (E5) and Fenugreek (E6) were tested using the RARg Transactivation Assay at a concentration of 50ug / ml on two separate days with duplicates on the first of two days. Extracts providing less than 15% receptor activation were considered inactive. Extracts providing greater than 25% receptor activation were active.

[0174] The results are shown in Table 4.

[0175] [Table 4]

[0176] In particular, the non-polar extracts of Calendula petals and Fenugreek leaves were significant RARg activators. In contrast, the other extracts from each of the two plants were found to be inactive when tested at a concentration of 50ug / mL.

[0177] Subsequent dose-response experiments using the RARg transactivation assay were performed with the two active extracts, E5 and E6, as well as with extracts of Acronitia acidula fruit (E1), Licaria vernicosa xylem (E2), Licaria vernicosa root (E3) and Actinomyces bacteria (E4), which had confirmed RARg activity in the RARg transactivation assay.

[0178] The results are shown in Table 5.

[0179] [Table 5]

[0180] The effect of the extract on cell viability was evaluated and no toxicity was observed.

[0181] Example 7 The compound 3-(4-farnesyloxyphenyl)-propionic acid was tested using the following RARg transactivation assay.

[0182] 3-(4-Farnesyloxyphenyl)-propionic acid was produced by Organix Inc., Woburn, Massachusetts, USA company. Following the general synthesis scheme, 100 mg of the compound was obtained with a purity of more than 98%. All spectroscopic data confirmed the structural configuration of 3-(4-farnesyloxyphenyl)-propionic acid.

[0183] The compound was tested as a solution in DMSO at different concentrations to assess the EC50 value, which was found to be 0.22 ug / mL.

[0184] Example 8 The effect of 3-(4-farnesyloxyphenyl)-propionic acid on skin hyperkeratinization was examined as follows.

[0185] Human epidermal skin equivalents from MatTek Company (Ashland, MA, USA) were used. Skin equivalents were topically treated with 10% oleic acid (OA) without or with 1 μM 3-(4-farnesyloxyphenyl)-propionic acid in proprietary MatTek medium (phenol red-free, hydrocortisone-free) for 48 h. Epidermal skin equivalents were harvested at the end of treatment, fixed in 10% neutral buffered formalin solution (Thermo Fisher Scientific, Hudson, NH, USA), dehydrated, and embedded in paraffin. Histological sections (5 μm thick) were cut and stained with hematoxylin-eosin. Three photographs per section were taken for each skin equivalent. The thickness of the stratum corneum or epidermis was measured using ImagePro Plus (Media Cybernetics Inc., Rockville, MD, USA). The thickness of the stratum corneum was expressed as % of the total epidermis (= stratum corneum thickness divided by the sum of the thickness of the stratum corneum and epidermis). The percentage of hyperkeratinization was normalized by the thickness of the 10% OA-treated tissue. Statistical analysis was performed using a two-tailed, two-sample, equal variance Student's t-test (Microsoft Office Excel 2007; Microsoft, Redmond, WA, USA).

[0186] The results are shown in Table 6.

[0187] [Table 6]

[0188] The results show that 3-(4-farnesyloxyphenyl)-propionic acid significantly (p<0.05) reduced oleic acid (OA)-induced hyperkeratinization of human epidermal skin equivalents.

[0189] Acne vulgaris is a disease of the pilosebaceous unit with a multifactorial etiology that includes hyperkeratinization. Excess unsaturated free fatty acids in the sebum of acne subjects may contribute to the impaired skin barrier associated with increased follicular stratum corneum thickness and inflammation seen in acne. It is known that oleic acid can induce hyperkeratinization in human epidermal skin equivalents that mimic acne lesion histology (Li, 2017). Thus, compositions according to the present invention containing 3-(4-farnesyloxyphenyl)-propionic acid may be advantageously used to treat acne and other conditions associated with hyperkeratinization.

[0190] [Embodiment] (1) A method for treating signs of skin aging, comprising topically applying to skin in need of treatment for the signs of skin aging a composition comprising an extract selected from the group consisting of an extract of Acronitzia acidula, an extract of Licaria vernicosa, an extract of Calendula officinalis, an extract of Fenugreek, an extract of Actinomyces, and combinations thereof. (2) The method of embodiment 1, wherein the extract is a polar extract of the fruit of Acronitia acidula. (3) The method of embodiment 1, wherein the extract is a polar extract of the xylem of Licaria vernicosa or the roots of Licaria vernicosa. (4) The method of embodiment 1, wherein the extract is a non-polar extract of calendula petals. (5) The method of embodiment 1, wherein the extract is a non-polar extract of fenugreek leaves.

[0191] (6) The method of embodiment 1, wherein the extract comprises greater than 0% and up to about 20% by weight of the composition. (7) The method of embodiment 1, wherein the composition also comprises a cosmetically acceptable carrier. (8) The method of embodiment 1, wherein the sign of skin aging is a decrease in collagen or elastin synthesis. (9) The method of embodiment 1, wherein the composition comprises 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester. (10) A method for improving skin barrier properties, comprising topically applying to skin in need of improved skin barrier function and moisturization a composition comprising an extract selected from the group consisting of an extract of Acronitzia acidula, an extract of Licaria vernicosa, an extract of Calendula officinalis, an extract of Fenugreek, an extract of Actinomyces bacteria, and combinations thereof.

[0192] (11) The method of embodiment 10, wherein the extract is a polar extract of the fruit of Acronitia acidula. (12) The method of embodiment 10, wherein the extract is a polar extract of the xylem of Licaria vernicosa or the roots of Licaria vernicosa. 13. The method of claim 10, wherein the extract is a non-polar extract of calendula petals. (14) The method of embodiment 10, wherein the extract is a non-polar extract of fenugreek leaves. (15) The method of embodiment 10, wherein the extract comprises more than 0% and up to about 20% by weight of the composition.

[0193] 16. The method of claim 10, wherein the composition also comprises a cosmetically acceptable carrier. (17) The method of embodiment 10, wherein the topical applying increases the level of hyaluronic acid in the skin. (18) The method of embodiment 10, wherein the composition comprises 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester. (19) A method for treating acne, comprising topically applying to skin in need of acne treatment a composition comprising an extract selected from the group consisting of an extract of Acronitzia acidula, an extract of Licaria vernicosa, an extract of Calendula officinalis, an extract of Fenugreek, an extract of Actinomyces, and combinations thereof. (20) The method of embodiment 19, wherein the extract is a polar extract of the fruit of Acronitia acidula.

[0194] (21) The method according to embodiment 19, wherein the extract is a polar extract of the xylem of Licaria vernicosa or the roots of Licaria vernicosa. 22. The method of claim 19, wherein the extract is a non-polar extract of calendula petals. (23) The method of embodiment 19, wherein the extract is a non-polar extract of fenugreek leaves. (24) The method of embodiment 19, wherein the extract comprises more than 0% and up to about 20% by weight of the composition. 25. The method of claim 19, wherein the composition also comprises a cosmetically acceptable carrier.

[0195] (26) The method of embodiment 19, wherein the composition comprises 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester.

Claims

1. 1. A method of treating signs of skin aging, comprising topically applying to skin in need of treatment for said signs of skin aging a composition comprising an extract of the fruit of Acronitia acidula; the sign of skin aging is a decrease in collagen or elastin synthesis, The method includes upregulating expression of a retinol responsive gene, The method (excluding medical procedures on humans), wherein the retinol responsive gene is a cellular retinoic acid binding protein-II (CRABP-II), HAS3, UGCG, and / or HbEGF gene.

2. 2. The method of claim 1, wherein the extract of the fruit of Acronitia acidula is a polar extract of the fruit of Acronitia acidula.

3. 2. The method of claim 1, wherein the extract of Acronitia acidula fruit comprises greater than 0.1% and up to about 2% by weight of the composition.

4. The method of claim 1 , wherein the composition also comprises a cosmetically acceptable carrier.

5. The method of claim 1, wherein the composition comprises 3-(4-farnesyloxyphenyl)-propionic acid and / or its ethyl ester.

6. The method described in claim 1, wherein the extract of the fruit of Acronitzia acidula increases elastin fiber and / or procollagen formation.

Citation Information

Patent Citations

  • Methods of lightening the skin

    US20130259815A1